3-[3-tert-butyl-4-(2-phenylethyl)phenyl]-5-(1-cyclopentyl-1H-isoindol-5-yl)-1,2,4-oxadiazole
C33H35N3O — CID 168858277
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[3-tert-butyl-4-(2-phenylethyl)phenyl]-5-(1-cyclopentyl-1H-isoindol-5-yl)-1,2,4-oxadiazole
3-[3-tert-butyl-4-(2-phenylethyl)phenyl]-5-(1-cyclopentyl-1H-isoindol-5-yl)-1,2,4-oxadiazole (PubChem CID 168858277) has the molecular formula C33H35N3O and a molecular weight of 489.66 g/mol. Its IUPAC name is 3-[3-tert-butyl-4-(2-phenylethyl)phenyl]-5-(1-cyclopentyl-1H-isoindol-5-yl)-1,2,4-oxadiazole.
Molecular Properties
| Compound Name | 3-[3-tert-butyl-4-(2-phenylethyl)phenyl]-5-(1-cyclopentyl-1H-isoindol-5-yl)-1,2,4-oxadiazole |
|---|---|
| PubChem CID | 168858277 |
| Molecular Formula | C33H35N3O |
| Molecular Weight | 489.66 g/mol |
| Exact Mass | 489.28 |
| IUPAC Name | 3-[3-tert-butyl-4-(2-phenylethyl)phenyl]-5-(1-cyclopentyl-1H-isoindol-5-yl)-1,2,4-oxadiazole |
| SMILES | CC(C)(C)c1cc(-c2noc(-c3ccc4c(c3)C=NC4C3CCCC3)n2)ccc1CCc1ccccc1 |
| InChI | InChI=1S/C33H35N3O/c1-33(2,3)29-20-25(16-15-23(29)14-13-22-9-5-4-6-10-22)31-35-32(37-36-31)26-17-18-28-27(19-26)21-34-30(28)24-11-7-8-12-24/h4-6,9-10,15-21,24,30H,7-8,11-14H2,1-3H3 |
| InChIKey | RHSQOTAPSOUNQM-UHFFFAOYSA-N |
| XLogP | 8.15 |
| TPSA | 51.28 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 37 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 489.66 |
| LogP ≤ 5 | 8.15 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 168858277 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.